Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients
This study has been completed.
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Information provided by:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT00475059
First received: May 16, 2007
Last updated: January 5, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Among the different creatinine-based GFR predicting equations, the MDRD equation gives the best prediction in renal transplantation but does not provide the level of accuracy usually seen in renal patients with native kidneys.
Blocking the tubular secretion of creatinine with an oral administration of cimetidine is likely to make creatinine a more accurate marker of GFR.
We will test the hypothesis that the accuracy of the MDRD equation will be improved in renal transplant patients by incorporating into the equation a cimetidine-corrected serum creatinine value.
| Condition | Intervention |
|---|---|
|
Kidney Transplantation |
Drug: cimetidine arrow |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients |
Resource links provided by NLM:
Further study details as provided by Centre Hospitalier Universitaire de Saint Etienne:
Primary Outcome Measures:
- performance of inulin clearance and MDRD with or no block of secretion renal tubule with cimetidine [ Time Frame: two days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Performance of different prediction equations for estimating renal function with or no block of secretion renal tubule with cimetidine : - Walser equation - Nankivell equation - Cockcroft and Gault equation [ Time Frame: two days ] [ Designated as safety issue: No ]
- comparison between inulin clearance and cystatin C [ Time Frame: two days ] [ Designated as safety issue: No ]
| Enrollment: | 59 |
| Study Start Date: | March 2007 |
| Study Completion Date: | March 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
patients who received cimétidine
|
Drug: cimetidine arrow
patients who received cimétidine
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Kidney transplantation > 1 year
- Patient with immunosuppressant treatment of TACROLIMUS (PROGRAF)
- Creatinine clearance > 30 ml/min/1,73m2 within 3 months before inclusion
- Written informed consent
- Patient affiliated to social insurance
Exclusion Criteria:
- Unstable renal function defined by serum creatinine (J0) > 25% serum creatinine realised in 3 months
- Treatment: Bactrim, Fansidar, Cimetidine arrow within the week before inclusion
- Contraindication listed in the labeling of Cimetidine arrow
- Last residual rate of Tacrolimus > 12 ng/ml.
- Treatment : carvedilol, phenytoïn (interaction with cimetidine)
- Serious hepatic insufficiency
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00475059
Locations
| France | |
| Nephrology unit, CHU Saint-Etienne | |
| Saint-Etienne, France, 42055 | |
Sponsors and Collaborators
Centre Hospitalier Universitaire de Saint Etienne
Investigators
| Principal Investigator: | Christophe Mariat, MD PhD | CHU-Saint-Etienne |
More Information
Publications:
| Responsible Party: | Clément CAILLAUX, Centre Hospitalier Universitaire de Saint Etienne |
| ClinicalTrials.gov Identifier: | NCT00475059 History of Changes |
| Other Study ID Numbers: | 0608090, 2006-005294-22 |
| Study First Received: | May 16, 2007 |
| Last Updated: | January 5, 2010 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) France: French Data Protection Authority |
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
|
kidney transplantation Glomerular filtration rate inulin clearance |
MDRD equation cystatin C cimetidine |
Additional relevant MeSH terms:
|
Cimetidine Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Histamine H2 Antagonists Histamine Antagonists |
Histamine Agents Neurotransmitter Agents Physiological Effects of Drugs Anti-Ulcer Agents Gastrointestinal Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013